Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification

被引:15
作者
Girolami, A
Simioni, P
Scarano, L
Girolami, B
Marchiori, A
机构
[1] Univ Padua, Sch Med, Inst Med Semeiot, I-35100 Padua, Italy
[2] Univ Padua, Sch Med, Chair Med 2, I-35100 Padua, Italy
关键词
D O I
10.1016/S0268-960X(98)90029-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The recent description of a factor V abnormality (factor V Leiden) associated with an increased incidence of thrombosis has considerably increased interest in this clotting factor. The discovery of this new clinical entity indicated the need for an updated classification of factor V defects. These should be divided into hemorrhagic and thrombotic disorders. A proper classification of hemorrhagic disorders should include: 1) homozygous and heterozygous 'true' factor V deficiency; and 2) combined factor V and factor VIII deficiencies. The latter should be subdivided in Type I (association type) and Type II (common defect). A suitable classification of the thrombotic factor V defects should include: I) homozygous and heterozygous factor V Leiden; and 2) combined heterozygous factor V Leiden and heterozygous 'true' factor V deficiency. The presence of thrombosis in these latter patients: often as severe as those seen in homozygous patients with activated protein C (APC) resistance, allows important considerations on the functions of factor V. It would seem that half the normal level of factor V activity and antigen is unable to protect against thrombosis in patients with heterozygous APC resistance. An accurate evaluation of factor V activity and antigen is indicated in all patient:; with suspected factor V defects. The first suspicion may be obtained by the presence of a mild prolongation of prothrombin time and of partial thromboplastin time. The suspicion should then be immediately confirmed by specific factor V activity and antigen assays. This approach is of great importance even for the presumptive diagnosis of pseudohomozygosis for APC resistance. In fact, in these cases, factor V activity is about 50% of normal, whereas factor V antigen is 100% of normal. In heterozygous 'true' factor V deficiency both activity and antigen are about 50% of normal.
引用
收藏
页码:45 / 51
页数:7
相关论文
共 41 条
[31]  
SEELER RA, 1972, MED CLIN N AM, V56, P119
[32]   The risk of recurrent venous thromboembolism in patients with an Arg(506)->Gln mutation in the gene for factor V (factor V Leiden) [J].
Simioni, P ;
Prandoni, P ;
Lensing, AWA ;
Scudeller, A ;
Sardella, C ;
Prins, MH ;
Villalta, S ;
Dazzi, F ;
Girolami, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (06) :399-403
[33]   HOMOZYGOUS FACTOR V-DEFICIENT PATIENTS SHOW RESISTANCE TO ACTIVATED PROTEIN-C WHEREAS HETEROZYGOTES DO NOT [J].
SIMIONI, P ;
GIROLAMI, A .
BLOOD COAGULATION & FIBRINOLYSIS, 1994, 5 (05) :825-827
[34]  
Simioni P, 1996, THROMB HAEMOSTASIS, V75, P422
[35]   ABNORMAL FORMATION OF THE PROTHROMBINASE COMPLEX - FACTOR-V DEFICIENCY AND RELATED DISORDERS [J].
TRACY, PB ;
MANN, KG .
HUMAN PATHOLOGY, 1987, 18 (02) :162-169
[36]  
vanBoven HH, 1996, THROMB HAEMOSTASIS, V75, P417
[37]   Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency [J].
Zehnder, JL ;
Jain, M .
BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 (03) :361-362
[39]   RESISTANCE TO ACTIVATED PROTEIN-C AS AN ADDITIONAL GENETIC RISK FACTOR IN HEREDITARY-DEFICIENCY OF PROTEIN-S [J].
ZOLLER, B ;
BERNTSDOTTER, A ;
DE FRUTOS, PG ;
DAHLBACK, B .
BLOOD, 1995, 85 (12) :3518-3523
[40]   Activated protein C resistance: Clinical implications [J].
Zoller, B ;
Hillarp, A ;
Dahlback, B .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1997, 3 (01) :25-32